Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

CompletedOBSERVATIONAL
Enrollment

800

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
HivHIV-1-infectionHIV Infections
Interventions
DRUG

DTG/3TC versus BIC/F/TAF

A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).

Trial Locations (1)

33401

Midway Specialty Care Center, West Palm Beach

All Listed Sponsors
lead

Midway Specialty Care Center

OTHER

NCT06393387 - Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States | Biotech Hunter | Biotech Hunter